|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,938.00 GBX | +1.89% |
|
+3.00% | +6.22% |
| 06-04 | GSK plc Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 11:40 AM | |
| 06-04 | GSK : Jefferies remains its Buy rating | ZD |
| Capitalization | 77.36B 103B 89.62B 82.23B 144B 9,861B 146B 977B 380B 4,769B 389B 380B 16,585B | P/E ratio 2026 * |
12.4x | P/E ratio 2027 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise value | 89.86B 120B 104B 95.51B 167B 11,454B 170B 1,135B 442B 5,539B 451B 441B 19,263B | EV / Sales 2026 * |
2.66x | EV / Sales 2027 * | 2.45x |
| Free-Float |
92.3% | Yield 2026 * |
3.61% | Yield 2027 * | 3.78% |
Last Transcript: GSK plc
| 06-04 | GSK : Jefferies remains its Buy rating | ZD |
| 06-02 | GSK : Deutsche Bank reaffirms its Neutral rating | ZD |
| 06-01 | GSK : JP Morgan reiterates its Sell rating | ZD |
| 05-29 | GSK : JP Morgan gives a Sell rating | ZD |
| 05-29 | GSK : UBS remains Neutral | ZD |
| 1 day | +1.89% | ||
| 1 week | +3.00% | ||
| Current month | +3.00% | ||
| 1 month | +3.36% | ||
| 3 months | -4.91% | ||
| 6 months | +7.37% | ||
| Current year | +6.22% |
| 1 week | 1,805 |  | 1,940 |
| 1 month | 1,690 | | 2,191 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-22 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 05-15 | Buy | Director | 2,301 | 0.0001% | ||
| 05-15 | Buy | Director | 74 | 0.0000% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.89% | +3.00% | +28.09% | +39.28% | 103B | |
| +0.55% | +2.39% | +46.96% | +155.36% | 1,009B | |
| +2.02% | +3.30% | +50.15% | +47.16% | 560B | |
| +1.02% | +4.37% | +19.70% | +67.78% | 401B | |
| +0.77% | -0.67% | +21.96% | +11.96% | 328B | |
| +2.24% | +0.41% | +28.53% | +17.12% | 288B | |
| +1.85% | +0.14% | +21.53% | +30.34% | 272B | |
| +4.43% | -3.11% | -42.11% | -49.56% | 194B | |
| +1.15% | +3.80% | +20.41% | +58.02% | 189B | |
| -0.02% | -3.92% | +14.85% | +69.50% | 160B | |
| Average | +1.59% | +1.32% | +21.01% | +44.70% | 350.51B | |
| Weighted average by Cap. | +1.36% | +1.98% | +30.13% | +69.61% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.76B 45.16B 39.1B 35.88B 62.88B 4,303B 63.86B 426B 166B 2,081B 170B 166B 7,237B | 35.41B 47.37B 41.02B 37.64B 65.95B 4,514B 66.99B 447B 174B 2,183B 178B 174B 7,591B |
| Net income | 6.29B 8.41B 7.28B 6.68B 11.71B 801B 11.89B 79.42B 30.91B 388B 31.57B 30.89B 1,348B | 6.71B 8.98B 7.78B 7.14B 12.5B 856B 12.7B 84.82B 33.01B 414B 33.72B 32.99B 1,439B |
| Net Debt | 12.49B 16.71B 14.47B 13.28B 23.27B 1,593B 23.64B 158B 61.44B 770B 62.75B 61.39B 2,679B | 9.44B 12.63B 10.94B 10.04B 17.59B 1,204B 17.86B 119B 46.43B 582B 47.43B 46.39B 2,024B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/06/26 | 1,938.00 p | +1.89% | 6,351,418 |
| 04/06/26 | 1,902.00 p | +2.73% | 12,975,300 |
| 03/06/26 | 1,851.50 p | +1.70% | 8,184,176 |
| 02/06/26 | 1,820.50 p | -1.19% | 6,581,792 |
| 01/06/26 | 1,842.50 p | -2.07% | 4,512,921 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition